Keros Therapeutics (KROS) Research & Development (2019 - 2026)
Keros Therapeutics' Research & Development was $22.33 million in Q2 2026, down 48.7% from $43.5 million a year earlier.
Powered by 
Analysis
Keros Therapeutics (KROS) Research & Development (2019 - 2026) Analysis & Trends
On a trailing twelve-month basis, Keros Therapeutics' Research & Development was $103.27 million through Jun 30, 2026, down 44.8% year-over-year; for FY2025, it was $129.64 million, down 25.3% from FY2024.
- Research & Development shows a five-year compound annual growth rate of 30.8% (FY2020 to FY2025).
- In earlier years, Research & Development was $173.63 million in FY2024 (+28.4%), $135.26 million in FY2023 (+55.0%), $87.27 million in FY2022 (+58.3%) and $55.14 million in FY2021 (+62.9%).
- Quarterly Research & Development has moved between $14.83 million (Q3 2021) and $49.23 million (Q3 2024) over five years.
- Compared with a year earlier, Research & Development was higher in four of the last seven quarters, with an average decline of 9.9%.
- The best year-over-year quarter for Research & Development over five years was Q2 2022 (growth of 133.2%); the worst was Q4 2025 (a decline of 60.7%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,132.34 Bn | 1,100.93 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 615.91 Bn | 534.44 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 505.47 Bn | 478.59 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 368.25 Bn | 322.63 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.18 Bn | 262.17 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 236.22 Bn | 191.62 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 190.68 Bn | 164.87 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.14 Bn | 116.79 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Keros Therapeutics | 224.54 Mn | -1.70 Bn | - | 22.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.33 Mn |
| Dec 31, 2025 | 17.91 Mn |
| Sep 30, 2025 | 19.52 Mn |
| Jun 30, 2025 | 43.50 Mn |
| Mar 31, 2025 | 48.71 Mn |
| Dec 31, 2024 | 45.63 Mn |
| Sep 30, 2024 | 49.23 Mn |
| Jun 30, 2024 | 40.52 Mn |
| Mar 31, 2024 | 38.26 Mn |
| Dec 31, 2023 | 37.49 Mn |
| Sep 30, 2023 | 34.14 Mn |
| Jun 30, 2023 | 32.53 Mn |
| Mar 31, 2023 | 31.09 Mn |
| Dec 31, 2022 | 24.87 Mn |
| Sep 30, 2022 | 21.04 Mn |
| Jun 30, 2022 | 23.28 Mn |
| Mar 31, 2022 | 18.08 Mn |
| Dec 31, 2021 | 18.83 Mn |
| Sep 30, 2021 | 14.83 Mn |
| Jun 30, 2021 | 9.98 Mn |
API Access
Keros Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=KROS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "KROS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=KROS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();